Reich, K., Simpson, E., Langley, R., Warren, R., Costanzo, A. ., Saeki, H., Almgren, P., Gjerum, L., Carlsson, A., Gooderham, M., Pinter, A., De Bruin Weller, M., & Blauvelt, A. (2023). Tralokinumab demonstrated a consistent safety profile with up to 42 months of treatment in moderate to severe atopic dermatitis: including adverse events of special interest. SKIN The Journal of Cutaneous Medicine, 7(2), s143. https://doi.org/10.25251/skin.7.supp.143